Core Focus

• Pre-seed funding round closed, raising $1.5 million to use for discovery and development.

• Established a partnership with Liquid Biosciences to discover novel biomarkers for autoimmune diseases.

These diseases include:
• Inflammatory Bowel Disease
• Rheumatoid Arthritis  
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis
‍
• Initiate partnership with SmartHealth Diagnostics for expertise and access to key laboratory services that dramatically speed up develop time and begin assay and test discovery and development.

• Successfully completed the analytical validation of its Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP). This milestone demonstrates the test's exceptional performance across critical parameters, including precision, repeatability, linearity, sensitivity, stability, and robustness.

• With a new company valuation, we began our second funding round for Clinical Validation and further developments.
‍

Begin Clinical Validity phase:
‍
 • 19-12 month period

 • 900 patients with inflammatory disease

• Partnership with SmartHealth Diagnostics and a large clinical research organization (CRO)

• Aim to obtain Clinical Laboratory Improvement Amendment (CLIA) certification

Pre-Launch Activities

 • Conduct clinical utility study

 • Test portfolio with Palmetto MolDX program
 • Negotiate pricing with Centers for Medicare & Medicaid Services (CMS)
 •Meet with managed care and health system executives
 • Commence general marketing and sales (primarily to Medicare patients)

Projects Overview:

 • IGNB-001A IBD TNFI Precision Blood Test
(Analytically Validated)

 • IGNB-001B RA TNFI Precision Blood Test
(In Discovery)

 • IGNB-001C PSA/PSO TNFI Precision Blood Test
 (In Discovery)

 • IGNB-002 IBD Diagnostic and Prognostic Blood Test
(Discovery Complete)

 •  IGNB-003 IBD Next-Gen a4B7 Precision Blood Test
(Discovery Complete)

 • IGNB-101 Substance Use Disorder Diagnostic (Discovery Complete)